Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Search

Page Path
HOME > Search
24 "Sung Yong Oh"
Filter
Filter
Article category
Keywords
More +
Publication year
More +
Authors
More +
Funded articles
More +
Original Articles
Hematologic malignancy
Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study
Yoon Seok Choi, Joonho Shim, Ka-Won Kang, Sang Eun Yoon, Jun Sik Hong, Sung Nam Lim, Ho-Young Yhim, Jung Hye Kwon, Gyeong-Won Lee, Deok-Hwan Yang, Sung Yong Oh, Ho-Jin Shin, Hyeon-Seok Eom, Dok Hyun Yoon, Hong Ghi Lee, Seong Hyun Jeong, Won Seog Kim, Seok Jin Kim
Cancer Res Treat. 2025;57(1):267-279.   Published online July 16, 2024
DOI: https://doi.org/10.4143/crt.2024.479
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea.
Materials and Methods
Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response.
Results
Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression.
Conclusion
This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles.
  • 1,174 View
  • 108 Download
Close layer
General
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, Dong-Hoe Koo, Jung Hun Kang, Chi Hoon Maeng, Hee Kyung Ahn, Sung Yong Oh, Dae-Won Lee, Joohyuk Sohn, So Yeon Oh, Kyung Hee Lee, Su-Jin Koh, Keun Seok Lee, Chan-Kyu Kim, Ji-Yeon Kim, Jun Ho Ji, Sung-Bae Kim, Joo Young Ha, Ho Young Kim
Cancer Res Treat. 2023;55(4):1096-1103.   Published online April 7, 2023
DOI: https://doi.org/10.4143/crt.2022.1565
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Several previous studies and case reports have reported ethanol-induced symptoms in patients receiving anticancer drugs containing ethanol. Most docetaxel formulations contain ethanol as a solvent. However, there are insufficient data on ethanol-induced symptoms when docetaxel-containing ethanol is administered. The primary purpose of this study was to investigate the frequency and pattern of ethanol-induced symptoms during and after docetaxel administration. The secondary purpose was to explore the risk factors for ethanol-induced symptoms.
Materials and Methods
This was a prospective, multicenter, observational study. The participants filled out ethanol-induced symptom questionnaire on the day of chemotherapy and the following day.
Results
Data from 451 patients were analyzed. The overall occurrence rate of ethanol-induced symptoms was 44.3% (200/451 patients). The occurrence rate of facial flushing was highest at 19.7% (89/451 patients), followed by nausea in 18.2% (82/451 patients), and dizziness in 17.5% (79/451 patients). Although infrequent, unsteady walking and impaired balance occurred in 4.2% and 3.3% of patients, respectively. Female sex, presence of underlying disease, younger age, docetaxel dose, and docetaxel-containing ethanol amount were significantly associated with the occurrence of ethanol-induced symptoms.
Conclusion
The occurrence of ethanol-induced symptoms was not low in patients receiving docetaxel-containing ethanol. Physicians need to pay more attention to the occurrence of ethanol-induced symptoms and prescribe ethanol-free or low-ethanol-containing formulations to high-risk patients.

Citations

Citations to this article as recorded by  
  • Evaluation of self-assembling properties of paclitaxel-biotin conjugates
    Dmitry V. Beigulenko, Anna Yu. Belyaeva, Ekaterina S. Kazakova, Maria M. Antonova, Aleksander S. Peregudov, Aleksey A. Nikitin, Tatyana S. Kovshova, Yulia V. Ermolenko, Konstantin A. Kochetkov
    Nano-Structures & Nano-Objects.2024; 40: 101375.     CrossRef
  • 3,490 View
  • 217 Download
  • 1 Crossref
Close layer
Hematologic malignancy
Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
Jun Ho Yi, Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Youngil Koh, Jin Seok Kim, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Whan Jung Yun, Yong Park, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Dae-Sik Hong, Ho-Sup Lee, Gyeong-Won Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2023;55(1):325-333.   Published online April 22, 2022
DOI: https://doi.org/10.4143/crt.2022.008
AbstractAbstract PDFPubReaderePub
Purpose
Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.
Materials and Methods
We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.
Results
Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).
Conclusion
In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population.

Citations

Citations to this article as recorded by  
  • Recent advances in cellular immunotherapy for lymphoid malignancies
    Haerim Chung, Hyunsoo Cho
    Blood Research.2023; 58(4): 166.     CrossRef
  • Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases
    Hongyu Chen, Junmin Wang, Caiyun Zhang, Peilun Ding, Shuxia Tian, Junming Chen, Guang Ji, Tao Wu
    Biomedicine & Pharmacotherapy.2022; 153: 113341.     CrossRef
  • 6,926 View
  • 346 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)
Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, Hoon-Gu Kim, Young Rok Do, Yong Park, Sung Yong Oh, Ho-Jin Shin, Won Seog Kim, Seong Kyu Park, Jee Hyun Kong, Moo-Rim Park, Deok-Hwan Yang, Jae-Yong Kwak, Hye Jin Kang, Yeung-Chul Mun, Jong-Ho Won
Cancer Res Treat. 2023;55(1):304-313.   Published online March 30, 2022
DOI: https://doi.org/10.4143/crt.2022.004
AbstractAbstract PDFPubReaderePub
Purpose
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard management for relapsed or high-risk non-Hodgkin’s lymphoma (NHL). We reported the busulfan, melphalan, and etoposide (BuME) conditioning regimen was effective in patients with relapsed or high-risk NHL. Moreover, the busulfan, cyclophosphamide, and etoposide (BuCE) conditioning regimen has been used widely in ASCT for NHL. Therefore, based on these encouraging results, this randomized phase II multicenter trial compared the outcomes of BuME and BuCE as conditioning therapies for ASCT in patients with NHL.
Materials and Methods
Patients were randomly assigned to receive either BuME (n=36) or BuCE (n=39). The BuME regimen was comprised of busulfan (3.2 mg/kg/day, intravenously) administered on days –7, –6, and –5, etoposide (400 mg/m2 intravenously) on days –5 and –4, and melphalan (50 mg/m2/day intravenously) on days –3 and –2. The BuCE regimen was comprised of busulfan (3.2 mg/kg/day intravenously) on days –7, –6, and –5, etoposide (400 mg/m2/day intravenously) on days –5 and –4, and cyclophosphamide (50 mg/kg/day intravenously) on days –3 and –2. The primary endpoint was 2-year progression-free survival (PFS).
Results
Seventy-five patients were enrolled. Eleven patients (30.5%) in the BuME group and 13 patients (33.3%) in the BuCE group had disease progression or died. The 2-year PFS rate was 65.4% in the BuME group and 60.6% in the BuCE group (p=0.746). There were no non-relapse mortalities within 100 days after transplantation.
Conclusion
There were no significant differences in PFS between the two groups. Therefore, busulfan-based conditioning regimens, BuME and BuCE, may be important treatment substitutes for the BCNU-containing regimens.

Citations

Citations to this article as recorded by  
  • CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-match
    Tao Wang, Ping Liu, Lili Xu, Lei Gao, Xiong Ni, Gusheng Tang, Li Chen, Jie Chen, Libing Wang, Yang Wang, Weijia Fu, Wenqin Yue, Na Liu, Ruobing Li, Guihua Lu, Yanrong Luo, Jianmin Yang
    Annals of Hematology.2024; 103(2): 575.     CrossRef
  • 5,591 View
  • 231 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study
Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim
Cancer Res Treat. 2022;54(4):1268-1277.   Published online December 30, 2021
DOI: https://doi.org/10.4143/crt.2021.1168
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Febrile neutropenia (FN) can cause suboptimal treatment and treatment-related mortality (TRM) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP).
Materials and methods
We conducted a prospective cohort study to evaluate the effectiveness of pegfilgrastim prophylaxis in DLBCL patients receiving R-CHOP, and we compared them with the PROCESS cohort (n=485).
Results
Since January 2015, 986 patients with DLBCL were enrolled. Pegfilgrastim was administered at least once in 930 patients (94.3%), covering 90.3% of all cycles. FN developed in 137 patients (13.9%) in this cohort (23.7% in the PROCESS cohort, p<0.001), and 4.2% of all cycles (10.2% in the PROCESS cohort, p<0.001). Dose delay was less common (≥3 days: 18.1% vs. 23.7%, p=0.015; ≥5 days: 12.0% vs. 18.3%, p=0.023) in this cohort than in the PROCESS cohort. The incidence of TRM (3.2% vs. 5.6%, p=0.047) and infection-related death (1.8% vs. 4.5%, p=0.004) was lower in this cohort than in the PROCESS cohort. The 4-year overall survival (OS) and progression-free survival (PFS) rates of the two cohorts were not different (OS: 73.0% vs. 71.9%, p=0.545; PFS: 69.5% vs. 68.8%, p=0.616). However, in patients aged ≥75 years, the 4-year OS and PFS rates were higher in this cohort than in the PROCESS cohort (OS: 49.6% vs. 33.7%, p=0.032; PFS: 44.2% vs. 30.3% p=0.047).
Conclusion
Pegfilgrastim prophylaxis is effective in the prevention of FN and infection-related death in DLBCL patients receiving R-CHOP, and it also improves OS in patients aged ≥75 years.
  • 7,406 View
  • 294 Download
  • 1 Web of Science
Close layer
Body Cavity–Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
Junghoon Shin, Young Hyeh Ko, Sung Yong Oh, Dok Hyun Yoon, Jeong-Ok Lee, Jin Seok Kim, Yong Park, Ho Jin Shin, Seok Jin Kim, Jong Ho Won, Sung-Soo Yoon, Won Seog Kim, Youngil Koh, On behalf of the Consortium for Improving Survival of Lymphoma investigators
Cancer Res Treat. 2019;51(4):1302-1312.   Published online February 14, 2019
DOI: https://doi.org/10.4143/crt.2018.555
AbstractAbstract PDFPubReaderePub
Purpose
Primary effusion lymphoma (PEL) is a type of body cavity–based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden.
Materials and Methods
We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea.
Results
Latency-associated nuclear antigen 1 (LANA1) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival.
Conclusion
PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.

Citations

Citations to this article as recorded by  
  • Space-associated lymphomas: review of a heterogeneous group of old and new entities
    Judith A Ferry
    Diagnostic Histopathology.2024; 30(8): 430.     CrossRef
  • A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients
    Julien Calvani, Laurence Gérard, Jehane Fadlallah, Elsa Poullot, Lionel Galicier, Cyrielle Robe, Margaux Garzaro, Remi Bertinchamp, David Boutboul, Wendy Cuccuini, Jean-Michel Cayuela, Philippe Gaulard, Éric Oksenhendler, Véronique Meignin
    American Journal of Surgical Pathology.2022; 46(3): 353.     CrossRef
  • A Rapidly Accumulating Effusion in an Immunocompetent Woman
    Zein Kattih, Akhilesh Mahajan, Morana Vojnic, Jordan Steinberg, Alyssa Yurovitsky, Jin Ah Kim, Amory Novoselac
    Chest.2022; 161(6): e377.     CrossRef
  • Human herpesvirus‐8–positive primary effusion lymphoma in HIV‐negative patients: Single institution case series with a multidisciplinary characterization
    Giovanni Rossi, Ilaria Cozzi, Irene Della Starza, Lucia Anna De Novi, Maria Stefania De Propris, Aurelia Gaeta, Luigi Petrucci, Alessandro Pulsoni, Federica Pulvirenti, Valeria Ascoli
    Cancer Cytopathology.2021; 129(1): 62.     CrossRef
  • Primary effusion lymphoma in human immune deficiency (HIV)‐negative non‐organ transplant immunocompetent patients
    Lisi Yuan, James R. Cook, Tarik M. Elsheikh
    Diagnostic Cytopathology.2020; 48(4): 380.     CrossRef
  • Clinicopathologic characteristics and survival of patients with primary effusion lymphoma
    Cristian Aguilar, Caddie Laberiano, Brady Beltran, Cecilia Diaz, Alvaro Taype-Rondan, Jorge J. Castillo
    Leukemia & Lymphoma.2020; 61(9): 2093.     CrossRef
  • 6,637 View
  • 157 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis
Jun Ho Ji, Young Saing Kim, Inkeun Park, Soon Il Lee, Rock Bum Kim, Joon Oh Park, Sung Yong Oh, In Gyu Hwang, Joung-Soon Jang, Haa-Na Song, Jung-Hun Kang
Cancer Res Treat. 2018;50(3):791-800.   Published online August 23, 2017
DOI: https://doi.org/10.4143/crt.2017.044
AbstractAbstract PDFPubReaderePub
Purpose
Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients.
Materials and Methods
Advanced BTC patientswith a good performance status (Eastern CooperativeOncologyGroup [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis.
Results
In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 ≤ 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA ≤ 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052).
Conclusion
Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.

Citations

Citations to this article as recorded by  
  • Observational Study of Best Supportive Care With or Without Oral Capecitabine in Patients With Metastatic Gallbladder Carcinoma at a Tertiary Center in India
    Abhinav Srivastava, Shagun Misra, Neeraj Rastogi, Vishwas Kapoor, Shaleen Kumar
    JCO Global Oncology.2025;[Epub]     CrossRef
  • National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
    Faisal Saud Dar, Zaigham Abbas, Irfan Ahmed, Muhammad Atique, Usman Iqbal Aujla, Muhammad Azeemuddin, Zeba Aziz, Abu Bakar Hafeez Bhatti, Tariq Ali Bangash, Amna Subhan Butt, Osama Tariq Butt, Abdul Wahab Dogar, Javed Iqbal Farooqi, Faisal Hanif, Jahanzai
    World Journal of Gastroenterology.2024; 30(9): 1018.     CrossRef
  • Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers
    Ali Belkouz, Elise de Savornin Lohman, Jyothi R. Thumma, Bas Groot Koerkamp, Philip R. de Reuver, Martijn G.H. van Oijen, Cornelis J.A. Punt, Hari Nathan, Heinz-Josef Klümpen
    Journal of Geriatric Oncology.2023; 14(3): 101447.     CrossRef
  • Main causes of death in advanced biliary tract cancer
    Kana Kimura‐Seto, Yasushi Kojima, Shiori Komori, Yuya Hisada, Yuki Otake, Yuka Yanai, Akiko Saito, Naoki Akazawa, Yasuo Tanaka, Chizu Yokoi, Mikio Yanase, Junichi Akiyama, Natsuyo Yamamoto, Kazuhiko Yamada
    Cancer Medicine.2023; 12(9): 10889.     CrossRef
  • A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
    Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
    Targeted Oncology.2023; 18(6): 837.     CrossRef
  • Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018
    Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-il Kim, Olumide Gbolahan
    Cancer Control.2023;[Epub]     CrossRef
  • Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
    Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
    Clinical Epidemiology.2023; Volume 15: 1069.     CrossRef
  • 8,228 View
  • 213 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis
Se-Il Go, Young Saing Kim, In Gyu Hwang, Eun Young Kim, Sung Yong Oh, Jun Ho Ji, Haa-Na Song, Se Hoon Park, Joon Oh Park, Jung Hun Kang
Cancer Res Treat. 2016;48(4):1274-1285.   Published online February 12, 2016
DOI: https://doi.org/10.4143/crt.2015.502
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to assess the role of adjuvant therapy in stage I-III gallbladder cancer (GBC) patients who have undergone R0 resection.
Materials and Methods
Clinical data were collected on 441 consecutive patients who underwent R0 resection for stage I-III GBC. Eligible patients were classified into adjuvant therapy and surveillance only groups. Propensity score matching (PSM) between the two groups was performed, adjusting clinical factors.
Results
In total, 84 and 279 patients treated with adjuvant therapy and followed up with surveillance only, respectively, were included in the analysis. Before PSM, the 5-year relapse-free survival (RFS) rate was lower in the adjuvant therapy group than in the surveillance only group (50.8% vs. 74.8%, p < 0.001), although there was no statistically significant difference in the 5-year overall survival (OS) rate (66.2% vs. 79.5%, p=0.089). After the PSM, baseline characteristics became comparable and there were no differences in the 5-year RFS (50.8% vs. 64.8%, p=0.319) and OS (66.2% vs. 70.4%, p=0.703) rates between the two groups.
Conclusion
The results suggest that fluoropyrimidine-based adjuvant therapy is not indicated in stage I-III GBC patients who have undergone R0 resection.

Citations

Citations to this article as recorded by  
  • Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection
    Sundeep Singh Saluja, Phani Kumar Nekarakanti, Pramod Kumar Mishra, Anurita Srivastava, Kishore Singh
    Journal of Gastrointestinal Surgery.2022; 26(2): 398.     CrossRef
  • Adjuvant Therapy for Resectable Biliary Tract Cancer: A Bayesian Network Analysis
    Xiuqiong Chen, Fanqiao Meng, Hua Xiong, Yanmei Zou
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Current standards and future perspectives in adjuvant treatment for biliary tract cancers
    Angela Lamarca, Julien Edeline, Mairéad G McNamara, Richard A Hubner, Masato Nagino, John Bridgewater, John Primrose, Juan W Valle
    Cancer Treatment Reviews.2020; 84: 101936.     CrossRef
  • Prognostic factors and patterns of loco-regional failure in patients with R0 resected gallbladder cancer
    Jung Ho Im, Woo Jung Lee, Chang Moo Kang, Ho Kyoung Hwang, Jinsil Seong
    HPB.2020; 22(8): 1168.     CrossRef
  • Prognostic Factors for Operated Gallbladder Cancer
    Bala Basak Oven Ustaalioglu, Ahmet Bilici, Mesut Seker, Umut Kefeli, Dincer Aydin, Serkan Celik, Tarik Demir, Burcak Erkol
    Journal of Gastrointestinal Cancer.2019; 50(3): 451.     CrossRef
  • Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer
    Abhay K. Kattepur, Shraddha Patkar, Mahesh Goel, Anant Ramaswamy, Vikas Ostwal
    Journal of Gastrointestinal Surgery.2019; 23(11): 2232.     CrossRef
  • A systematic review of the effectiveness of adjuvant therapy for patients with gallbladder cancer
    Carlos Manterola, Galo Duque, Luis Grande, Xabier de Aretxabala, Roque Conejeros, Tamara Otzen, Nayely García
    HPB.2019; 21(11): 1427.     CrossRef
  • Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis
    Byoung Hyuck Kim, Jeanny Kwon, Eui Kyu Chie, Kyubo Kim, Young Hoon Kim, Dong Wan Seo, Amol K. Narang, Joseph M. Herman
    Annals of Surgical Oncology.2018; 25(1): 255.     CrossRef
  • Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer
    T Ebata, S Hirano, M Konishi, K Uesaka, Y Tsuchiya, M Ohtsuka, Y Kaneoka, M Yamamoto, Y Ambo, Y Shimizu, F Ozawa, A Fukutomi, M Ando, Y Nimura, M Nagino, S Nakamori, T Ajiki, H Baba, R Yamaguchi, M Kawai, H Nagano, F Miura, T Arai, Y Nishiwaki, S Kawasaki
    British Journal of Surgery.2018; 105(3): 192.     CrossRef
  • Adjuvant systemic therapy and postoperative outcomes after resection of node positive gallbladder cancer
    Jiong-Jie Yu, Xin-Fei Xu, Tian Yang
    International Journal of Surgery.2018; 54: 307.     CrossRef
  • The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer
    Luxi Yin, Qi Xu, Jingjing Li, Qing Wei, Jieer Ying
    Medicine.2018; 97(50): e13570.     CrossRef
  • Surgical Management of Gallbladder Cancer
    Gyulnara G. Kasumova, Omidreza Tabatabaie, Robert M. Najarian, Mark P. Callery, Sing Chau Ng, Andrea J. Bullock, Robert A. Fisher, Jennifer F. Tseng
    Annals of Surgery.2017; 266(4): 625.     CrossRef
  • 15,047 View
  • 203 Download
  • 18 Web of Science
  • 12 Crossref
Close layer
Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study
Myung Ah Lee, Eun Kyung Cho, Sung Yong Oh, Joong Bae Ahn, Ji Yun Lee, Burke Thomas, Hun Jung, Jong Gwang Kim
Cancer Res Treat. 2016;48(4):1420-1428.   Published online February 12, 2016
DOI: https://doi.org/10.4143/crt.2015.309
AbstractAbstract PDFPubReaderePub
Purpose
This study reported patient outcomes of chemotherapy-induced nausea and vomiting (CINV) prophylaxis for highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens and evaluated its adherence to acute-phase CINV prophylaxis in the Korean population subset of the Pan Australasian Chemotherapy Induced Emesis burden of illness (PrACTICE) study. Materials and Methods This subgroup analysis evaluated 158 Korean patients receiving HEC or MEC and compared the data (wherever possible) with that of 648 patients from the Asia-Pacific (AP) region. Study endpoints included evaluation of primary CINV prophylaxis and adherence to acutephase CINV prophylaxis in cycle 1 (American Society of Clinical Oncology [ASCO] Quality Oncology Practice Initiative [QOPI]).
Results
In South Korea and the AP, a 5-hydroxytryptamine-3 receptor antagonist (5HT3-RA) prophylaxis for the acute phase was administered to 79/80 patients (98.8%) for HEC and 70/71 patients (98.6%) for MEC regimens (QOPI-1). Triple regimen (corticosteroid–5HT3-RA–neurokinin 1-RA) was initiated in 46/80 patients (57.5%) for prophylaxis of acute CINV in cycle 1 of HEC (QOPI-3). Double regimen (corticosteroid–5HT3-RA, with or within NK1-RA) was initiated in 61/71 patients (83.1%) for control of acute CINV in cycle 1 of MEC a(QOPI-2). Conclusion Active management of CINV is necessary in cycle 1 of HEC in South Korea, despite higher rates than the AP region. Adherence to the international guidelines for CINV prophylaxis requires attention in the acute phase in cycle 1 of the HEC regimen.

Citations

Citations to this article as recorded by  
  • Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea
    Ryugyoung Lee, Minhee Ku, Nam Kyung Je
    Supportive Care in Cancer.2024;[Epub]     CrossRef
  • Chemotherapy-Associated Nausea and Vomiting
    Kelvin Mogesa Manyega, Benjamin Nasara Joseph, Okunlola Charity Rotkangmwa, Maxwell P. Dapar
    Annals of African Medicine.2022; 21(2): 124.     CrossRef
  • Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective
    Ashok K. Vaid, Sudeep Gupta, Dinesh C. Doval, Shyam Agarwal, Shona Nag, Poonam Patil, Chanchal Goswami, Vikas Ostwal, Sagar Bhagat, Saiprasad Patil, Hanmant Barkate
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Construção e avaliação de bundle frente ao extravasamento de antineoplásicos: estudo metodológico
    João Marcos Alves Melo, Patrícia Peres de Oliveira, Andrea Bezerra Rodrigues, Raíssa Silva Souza, Deborah Franscielle da Fonseca, Thaís Fonseca Gontijo, Edilene Aparecida Araújo da Silveira
    Acta Paulista de Enfermagem.2020;[Epub]     CrossRef
  • A cost-utility analysis of risk model-guided versus physician’s choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach
    Kednapa Thavorn, Doug Coyle, Jeffrey S. Hoch, Lisa Vandermeer, Sasha Mazzarello, Zhou Wang, George Dranitsaris, Dean Fergusson, Mark Clemons
    Supportive Care in Cancer.2017; 25(8): 2505.     CrossRef
  • 10,421 View
  • 152 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Jun Ho Yi, Jung Hun Kang, In Gyu Hwang, Hee Kyung Ahn, Hyun Jin Baek, Soon Il Lee, Do Hyoung Lim, Young-Woong Won, Jun Ho Ji, Hyo Song Kim, Sun Young Rha, Sung Yong Oh, Kyung Eun Lee, Taekyu Lim, Chi Hoon Maeng, Moon Jin Kim, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Se Hoon Park
Cancer Res Treat. 2016;48(2):553-560.   Published online August 10, 2015
DOI: https://doi.org/10.4143/crt.2015.155
AbstractAbstract PDFPubReaderePub
Purpose
While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy.
Materials and Methods
Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively.
Results
A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025).
Conclusion
While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer.

Citations

Citations to this article as recorded by  
  • Timing to Surgery and Lymph Node Upstaging in Gastric Cancer: An NCDB Analysis
    Maria Cristina Riascos, Jacques A. Greenberg, Federico Palacardo, Rodrigo Edelmuth, V. Colby Lewis, Anjile An, Haythem Najah, Hala Al Asadi, Parima Safe, Brendan M. Finnerty, Paul J. Christos, Thomas J. Fahey, Rasa Zarnegar
    Annals of Surgical Oncology.2024; 31(3): 1714.     CrossRef
  • Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study
    Katharina Kolbe, Ivonne Haffner, Katrin Schierle, Dieter Maier, Birgitta Geier, Birgit Luber, Hendrik Bläker, Christian Wittekind, Florian Lordick
    Journal of Cancer Research and Clinical Oncology.2023; 149(3): 1319.     CrossRef
  • Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer
    Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Bum Jun Kim, Hyunki Kim, Un-Jung Yun, Jingmin Che, Sejung Park, Tae Soo Kim, Woo Sun Kwon, Juin Park, Sang Woo Cho, Chung Mo Nam, Hyun C
    Journal of Clinical Oncology.2023; 41(27): 4394.     CrossRef
  • Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
    Juin Park, Sun Kyoung Kang, Woo Sun Kwon, Inhye Jeong, Tae Soo Kim, Seo Young Yu, Sang Woo Cho, Hyun Cheol Chung, Sun Young Rha
    Scientific Reports.2023;[Epub]     CrossRef
  • Do proton pump inhibitors affect the effectiveness of chemotherapy in colorectal cancer patients? A systematic review with meta-analysis
    Wan-Ying Lin, Shih-Syuan Wang, Yi-No Kang, Andrea S. Porpiglia, Yu Chang, Chin-Hsuan Huang, Ronak Bhimani, Eahab Abdul-Lattif, Muneeba Azmat, Tsu-Hsien Wang, Yu-Shiuan Lin, Yu-Cheng Chang, Kuan-Yu Chi
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer
    S.J. Merchant, W. Kong, B. Gyawali, T. Hanna, W. Chung, S. Nanji, S.V. Patel, C.M. Booth
    Clinical Oncology.2021; 33(3): 202.     CrossRef
  • Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
    Tae-Hwan Kim, Hun Do Cho, Yong Won Choi, Hyun Woo Lee, Seok Yun Kang, Geum Sook Jeong, Jin-Hyuk Choi, Mi Sun Ahn, Seung-Soo Sheen
    BMC Cancer.2021;[Epub]     CrossRef
  • HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study
    Ivonne Haffner, Katrin Schierle, Elba Raimúndez, Birgitta Geier, Dieter Maier, Jan Hasenauer, Birgit Luber, Axel Walch, Katharina Kolbe, Jorge Riera Knorrenschild, Albrecht Kretzschmar, Beate Rau, Ludwig Fischer von Weikersthal, Miriam Ahlborn, Gabriele S
    Journal of Clinical Oncology.2021; 39(13): 1468.     CrossRef
  • Current therapeutic options for gastric adenocarcinoma
    C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
    Saudi Journal of Biological Sciences.2021; 28(9): 5371.     CrossRef
  • Efficacy of Trastuzumab and Potential Risk Factors on Survival in Patients with HER2-Positive Metastatic Gastric Cancer
    Atakan Topcu, Muhammed Mustafa Atci, Saban Secmeler, Mehmet Besiroglu, Murat Ayhan, Metin Ozkan, Oktay Bozkurt, Zuhat Urakci, Seval Ay, Caglayan Geredeli, Ayse Irem Yasin, Haci Mehmet Turk
    Future Oncology.2021; 17(31): 4157.     CrossRef

  • Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States


    Lisa M Hess, Michael Grabner, Liya Wang, Astra M Liepa, Xiaohong Ivy Li, Zhanglin Lin Cui, Lee Bowman, William R Schelman
    Pragmatic and Observational Research.2020; Volume 11: 27.     CrossRef
  • Targeting HER2-positive gastric cancer with a novel 18F-labeled ZHER2:342 probe
    Yunyun Pan, Zhengyang Yang, Yuping Xu, Zhicheng Bai, Donghui Pan, Runlin Yang, Lizhen Wang, Wenxian Guan, Min Yang
    RSC Advances.2019; 9(19): 10990.     CrossRef
  • Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients
    Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee
    Gastric Cancer.2018; 21(2): 225.     CrossRef
  • Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
    A. Ilhan-Mutlu, H. Taghizadeh, A. Beer, W. Dolak, A. Ba-Ssalamah, S. F. Schoppmann, M. Hejna, P. Birner, M. Preusser
    Cancer Biology & Therapy.2018; 19(3): 169.     CrossRef
  • Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
    Giandomenico Roviello, Roberto Petrioli, Valerio Nardone, Pietro Rosellini, Andrea Giovanni Multari, Raffaele Conca, Michele Aieta
    Medicine.2018; 97(20): e10745.     CrossRef
  • 14,335 View
  • 166 Download
  • 18 Web of Science
  • 15 Crossref
Close layer
Clinical Significance of Peroxisome Proliferator-Activated Receptor γ and TRAP220 in Patients with Operable Colorectal Cancer
Kyung A Kwon, Jeanho Yun, Sung Yong Oh, Bong-Gun Seo, Suee Lee, Ji-Hyun Lee, Sung-Hyun Kim, Hong Jo Choi, Mee Sook Roh, Hyo-Jin Kim
Cancer Res Treat. 2016;48(1):198-207.   Published online June 23, 2015
DOI: https://doi.org/10.4143/crt.2015.024
AbstractAbstract PDFPubReaderePub
Purpose
The peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that regulates expression of mediators of lipid metabolism and the inflammatory response. Thyroid hormone receptor-associated proteins 220 (TRAP220) is an essential component of the TRAP/Mediator complex. The objective of this study was to clarify whether PPARγ or TRAP220 are significant prognostic markers in resectable colorectal cancer (CRC).
Materials and Methods
A total of 399 patients who underwent curative resection for CRC were enrolled. We investigated the presence of PPARγ and TARP220 in CRC tissues and adjacent normal tissues by immunohistochemistry. Correlation between the expression of these factors and clinicopathologic features and survival was investigated.
Results
Median age of the patients was 63 years (range, 22 to 87 years), and median follow-up duration 61.1 months (range, 2 to 114 months). PPARγ and TRAP220 expression showed significant correlation with depth of invasion (p=0.013 and p=0.001, respectively). Expression of TRAP220 also showed association with lymph node metastasis and TNM stage (p=0.001). Compared with patients with TRAP220 negative tumors, patients with TRAP220 positive tumors had longer 5-year disease-free survival (DFS) tendency (p=0.051). Patients who were PPARγ positive combined with TRAP220 positive had a better 5-year DFS (64.8% vs. 79.3%, p=0.013). In multivariate analysis expression of both PPARγ and TRAP220 significantly affected DFS (hazard ratio, 0.620; 95% confidence interval, 0.379 to 0.997; p=0.048).
Conclusion
TRAP220 may be a valuable marker for nodal metastasis and TNM stage. Tumor co-expression of PPARγ and TRAP220 represents a biomarker for good prognosis in CRC patients.

Citations

Citations to this article as recorded by  
  • Expression of Peroxisome Proliferator-Activated Receptor γ in Human Colorectal Carcinoma and Its Correlation with Clinicopathological Characteristics
    Deepsikha Dharamsaktu, Jyotsna Naresh Bharti, Poonam Elhence, Meenakshi Rao, Jeewan Ram Vishnoi, Subash Chandra Soni, Neeti Rustagi
    Indian Journal of Surgical Oncology.2024;[Epub]     CrossRef
  • The Role of Fatty Acid Metabolism, the Related Potential Biomarkers, and Targeted Therapeutic Strategies in Gastrointestinal Cancers
    Ruixi Xie, Ying Luo, Bowen Bao, Xinshu Wu, Jia Guo, Jin Wang, Xiujuan Qu, Xiaofang Che, Chunlei Zheng
    Drug Development Research.2024;[Epub]     CrossRef
  • A review on the molecular mechanisms, the therapeutic treatment including the potential of herbs and natural products, and target prediction of obesity-associated colorectal cancer
    Huihai Yang, Grace Gar Lee Yue, Ping Chung Leung, Chun Kwok Wong, Clara Bik San Lau
    Pharmacological Research.2022; 175: 106031.     CrossRef
  • UCP2 as a Cancer Target through Energy Metabolism and Oxidative Stress Control
    Angèle Luby, Marie-Clotilde Alves-Guerra
    International Journal of Molecular Sciences.2022; 23(23): 15077.     CrossRef
  • Lycopene supplementation regulates the gene expression profile and fat metabolism of breeding hens
    Hanchen Tian, Guangbin Liu, Yongqing Guo, Yaokun Li, Ming Deng, Dewu Liu, Baoli Sun
    Journal of Animal Physiology and Animal Nutrition.2020; 104(3): 936.     CrossRef
  • Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ
    Jing Zhou, Zhanzhao Liu, Lingjing Zhang, Xiao Hu, Zhihua Wang, Hong Ni, Yue Wang, Junfang Qin
    Cancer Research and Treatment.2020; 52(3): 830.     CrossRef
  • Checkpoint-dependent phosphorylation of Med1/TRAP220 in response to DNA damage
    Hyun-Ju Kim, Jeanho Yun
    Acta Biochimica et Biophysica Sinica.2017; 49(6): 496.     CrossRef
  • Expression and role of nuclear receptor coregulators in colorectal cancer
    Mouna Triki, Marion Lapierre, Vincent Cavailles, Raja Mokdad-Gargouri
    World Journal of Gastroenterology.2017; 23(25): 4480.     CrossRef
  • 11,389 View
  • 64 Download
  • 8 Web of Science
  • 8 Crossref
Close layer
Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis
Junshik Hong, Seok Jin Kim, Jae-Sook Ahn, Moo Kon Song, Yu Ri Kim, Ho Sup Lee, Ho-Young Yhim, Dok Hyun Yoon, Min Kyoung Kim, Sung Yong Oh, Yong Park, Yeung-Chul Mun, Young Rok Do, Hun-Mo Ryoo, Je-Jung Lee, Jae Hoon Lee, Won Seog Kim, Cheolwon Suh
Cancer Res Treat. 2015;47(2):173-181.   Published online October 28, 2014
DOI: https://doi.org/10.4143/crt.2014.055
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma (BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD) regimen by focusing on tolerability and actual delivered relative dose intensity (RDI).
Materials and Methods
Patients ≥ 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphoma were treated with at least one cycle of R-hyper-CVAD as the first-line treatment in this study. Eligible patients’ case report forms were requested from their physicians to obtain clinical and laboratory data for this retrospective study.
Results
Forty-three patients (median age, 51 years) from 14 medical centers in Korea were analyzed, none of which were infected with human immunodeficiency virus. The majority of patients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rates were 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete the R-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin, vincristine, methotrexate, and cytarabine were between 60% and 65%, which means less than 25% of patients received greater than 80% of the planned dose of each drug. Poor performance status was related to the lower RDIs of doxorubicin and methotrexate.
Conclusion
R-hyper-CVAD showed excellent treatment outcomes in patients who were suitable for dose-intense chemotherapy. However, management of patients who are intolerant to a dose-intense regimen remains problematic due to the frequent occurrence of treatmentrelated complications.

Citations

Citations to this article as recorded by  
  • Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis
    Xiaoxuan Lu, Yu Liu, Ruyu Liu, Jiaxin Liu, Xiaojing Yan, Liren Qian
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
    Ze‐Long Liu, Pan‐Pan Liu, Xi‐Wen Bi, De‐Xin Lei, Yu Wang, Zhi‐Ming Li, Wen‐Qi Jiang, Yi Xia
    Cancer Medicine.2019; 8(3): 874.     CrossRef
  • ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines
    Jun Liu, Junshik Hong, Kwang-Sung Ahn, Junhyeok Go, Heejoo Han, Jihyun Park, Dongchan Kim, Hyejoo Park, Youngil Koh, Dong-Yeop Shin, Sung-Soo Yoon
    Leukemia & Lymphoma.2019; 60(10): 2532.     CrossRef
  • Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
    Kwai Han Yoo, Hyewon Lee, Cheolwon Suh
    International Journal of Hematology.2018; 107(4): 395.     CrossRef
  • Recent advances in treating extra-ocular lymphomas
    Lauge Hjorth Mikkelsen, Natacha Storm Würtz, Steffen Heegaard
    Expert Review of Ophthalmology.2018; 13(4): 205.     CrossRef
  • The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
    Cheolwon Suh, Byeong-Bae Park, Won Seog Kim
    Blood Research.2017; 52(1): 3.     CrossRef
  • Primary lymphomas in the gastrointestinal tract
    Jiang Chen Peng, Lu Zhong, Zhi Hua Ran
    Journal of Digestive Diseases.2015; 16(4): 169.     CrossRef
  • 15,799 View
  • 142 Download
  • 10 Web of Science
  • 7 Crossref
Close layer
Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study
Seong Hoon Shin, Ho Sup Lee, Yang Soo Kim, Young Jin Choi, Sung Hyun Kim, Hyuk Chan Kwon, Sung Yong Oh, Jung Hun Kang, Chang Hak Sohn, Sang Min Lee, Jin Ho Baek, Young Joo Min, Choongrak Kim, Joo Seop Chung
Cancer Res Treat. 2014;46(4):331-338.   Published online July 21, 2014
DOI: https://doi.org/10.4143/crt.2013.130
AbstractAbstract PDFPubReaderePub
Purpose
To evaluate the efficacy of hydromorphone-OROS (HM-OROS) in reducing sleep disturbance and relieving cancer pain. Materials and Methods One hundred twenty cancer patients with pain (numeric rating scale [NRS] ≥ 4) and sleep disturbance (NRS ≥ 4) were evaluated. The initial HM-OROS dosing was based on previous opioid dose (HM-OROS:oral morphine=1:5). Dose adjustment of the study drug was permitted at the investigator’s discretion. Pain intensity, number of breakthrough pain episodes, and quality of sleep were evaluated. Results A total of 120 patients received at least one dose of HM-OROS; 74 of them completed the final assessment. Compared to the previous opioids, HM-OROS reduced the average pain NRS from 5.3 to 4.1 (p < 0.01), worst pain NRS from 6.7 to 5.4 (p < 0.01), sleep disturbance NRS from 5.9 to 4.1 (p < 0.01), incidence of breakthrough pain at night from 2.63 to 1.53 times (p < 0.001), and immediate-release opioids use for the management of breakthrough pain from 0.83 to 0.39 times per night (p = 0.001). Of the 74 patients who completed the treatment, 83.7% indicated that they preferred HM-OROS to the previous medication. The adverse events (AEs) were somnolence, asthenia, constipation, dizziness, and nausea. Conclusion HM-OROS was efficacious in reducing cancer pain and associated sleep disturbances. The AEs were manageable.

Citations

Citations to this article as recorded by  
  • Pain and Analgesic Related Insomnia
    Jana Mlíchová, Zoltán Paluch, Ondřej Šimandl
    Pain Management Nursing.2023; 24(3): 254.     CrossRef
  • Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients
    Mi-Young Kwon, Ha-Na Cho, Dong-Hoe Koo, Yun-Gyoo Lee, Sukjoong Oh, Seung-Sei Lee
    The Korean Journal of Internal Medicine.2018; 33(3): 577.     CrossRef
  • Endogenous Opiates and Behavior: 2015
    Richard J. Bodnar
    Peptides.2017; 88: 126.     CrossRef
  • Drug Formulation Advances in Extended-Release Medications for Pain Control
    Mark R. Jones, Martin J. Carney, Rachel J. Kaye, Amit Prabhakar, Alan D. Kaye
    Current Pain and Headache Reports.2016;[Epub]     CrossRef
  • The Clinical Applications of Extended-Release Abuse-Deterrent Opioids
    Nalini Vadivelu, Erika Schermer, Gopal Kodumudi, Jack M. Berger
    CNS Drugs.2016; 30(7): 637.     CrossRef
  • Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study
    Cheol Kyu Park, Hyun-Wook Kang, In-Jae Oh, Young-Chul Kim, Yeo-Kyeoung Kim, Kook-Joo Na, Sung-Ja Ahn, Tae Ok Kim, Young Jin Choi, Geun Am Song, Min Ki Lee
    Journal of Korean Medical Science.2016; 31(12): 1914.     CrossRef
  • 13,202 View
  • 81 Download
  • 6 Crossref
Close layer
Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee
Kyung A Kwon, Sung Yong Oh, Ho Young Kim, Hyo Song Kim, Ha Young Lee, Tae Min Kim, Ho Yeong Lim, Na-Ri Lee, Hyo Jin Lee, Sook Hee Hong, Sun Young Rha
Cancer Res Treat. 2014;46(2):141-147.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.141
AbstractAbstract PDFPubReaderePub
Purpose

Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.

Materials and Methods

From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.

Results

Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.

Conclusion

CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.

Citations

Citations to this article as recorded by  
  • Urothelial Carcinoma of the Renal Pelvis with Synchronous Ipsilateral Collecting Duct Carcinoma: Two Case Reports
    Sang Bin Bae, Seong Kuk Yoon, Seo-hee Rha
    Journal of the Korean Society of Radiology.2024; 85(1): 222.     CrossRef
  • A curious case: Concurrent collecting duct renal cell carcinoma and upper tract urothelial carcinoma
    Adib Rahman, Daniel Matheson, Joanna Perry-Keene, Devang Desai
    Urology Case Reports.2024; 54: 102698.     CrossRef
  • Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning
    Tianyi Shi, Xiucai Ye, Dong Huang, Tetsuya Sakurai
    Methods.2024; 231: 144.     CrossRef
  • Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies
    Zoé Guillaume, Yves Allory, Edouard Auclin, Claire Gervais, Marie Auvray, Adrien Rochand, Arnaud Mejean, François Audenet, Yann-Alexandre Vano, Stéphane Oudard, Constance Thibault
    Bulletin du Cancer.2023; 110(4): 450.     CrossRef
  • Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
    Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu
    Cancers.2022; 14(7): 1678.     CrossRef
  • Uncommon malignant renal tumors and atypical presentation of common ones: a guide for radiologists
    Benjamin Laguna, Antonio C. Westphalen, C. T. Guimarães, Zhen Whang, Jeff Simko, Ronald Zagoria
    Abdominal Radiology.2019; 44(4): 1430.     CrossRef
  • Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors
    A. Pinto, M. Garrido, C. Aguado, T. Alonso, P. Gajate, C. Maximiano, I. García-Carbonero, A. Martín, I. Gallegos, J.A. Arranz, J. Puente, E. Grande
    Kidney Cancer.2019; 3(3): 177.     CrossRef
  • Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
    Meghan Salgia, Jacob Adashek, Paulo Bergerot, Sumanta K. Pal
    Kidney Cancer.2017; 1(2): 99.     CrossRef
  • Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
    Gabriel G. Malouf, Eva Compérat, Hui Yao, Roger Mouawad, Veronique Lindner, Nathalie Rioux-leclercq, Virginie Verkarre, Xavier Leroy, Linda Dainese, Marion Classe, Jean-Luc Descotes, Philippe Barthelemy, Mokrane Yacoub, Morgan Rouprêt, Jean-Christophe Ber
    Scientific Reports.2016;[Epub]     CrossRef
  • Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases
    ZHENSHAN SHI, QIAN ZHUANG, RUIXIONG YOU, YUEMING LI, JIAN LI, DAIRONG CAO
    Oncology Letters.2016; 11(1): 261.     CrossRef
  • Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation
    Jianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, Lei Wei, Biao Liu, Qiang Hu, Kiersten Marie Miles, Jeffrey M. Conroy, Sean T. Glenn, Manuela Costantini, Cristina Magi-Galluzzi, Sabina Signoretti, Toni Choueiri, Michele Gallucci, Steno Se
    Oncotarget.2016; 7(21): 29901.     CrossRef
  • 11,899 View
  • 73 Download
  • 15 Web of Science
  • 11 Crossref
Close layer
Chemotherapy in Advanced Gastric Cancer Patients Associated with Disseminated Intravascular Coagulation
In Gyu Hwang, Jin Hwa Choi, Se Hoon Park, Sung Yong Oh, Hyuk-Chan Kwon, Soon Il Lee, Do Hyoung Lim, Gyeong-Won Lee, Jung Hun Kang
Cancer Res Treat. 2014;46(1):27-32.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.27
AbstractAbstract PDFPubReaderePub
PURPOSE
Little is known about the clinical features of advanced gastric cancer (AGC) combined with disseminated intravascular coagulation (DIC). The main objective of this study was to determine the clinical outcome of patients with AGC complicated by DIC.
MATERIALS AND METHODS
We conducted a retrospective review of 68 AGC patients diagnosed with DIC at four tertiary medical centers between January 1995 and June 2010.
RESULTS
Sixty eight patients were included. The median age was 55 years (range, 25 to 78 years). Nineteen patients received chemotherapy, whereas 49 patients received only best supportive care (BSC). The median overall survival (OS) of the 68 patients was 16 days (95% confidence interval [CI], 11 to 21 days). Significantly prolonged OS was observed in the chemotherapy group, with a median survival of 61 days compared to 9 days in the BSC group (p<0.001, log-rank test). Age and previous chemotherapy were another significant factors that were associated with OS in univariate analysis. In multivariate analysis, age (> or =65 vs. <65; hazard ratio [HR], 0.38; 95% CI, 0.18 to 0.78; p<0.001), chemotherapy (BSC vs. chemotherapy; HR 0.31; 95% CI, 0.15 to 0.63; p<0.001), and previous chemotherapy (yes or no; HR, 0.49; 95% CI, 0.25 to 0.98; p<0.045) were consistently independent prognostic factors that impacted OS.
CONCLUSION
Our study showed that patients with AGC complicated by DIC had very poor OS, and suggested that chemotherapy might improve OS of these patients.

Citations

Citations to this article as recorded by  
  • Long-term survival of a patient with gastric cancer with bone marrow metastasis receiving S-1 plus oxaliplatin beyond three years: a case report and literature review
    Hirotaka Suto, Yumiko Inui, Atsuo Okamura
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Metastatic gastric adenocarcinoma discovered in the bone marrow
    Ekaterina Proskuriakova, Vaisny Balamurali, Anuradha Hooda, Paramjeet Khosla
    BMJ Case Reports.2024; 17(9): e260217.     CrossRef
  • Case report: PD-1 inhibitor-based treatment strategies in gastric cancer complicated by bone marrow metastasis and disseminated intravascular coagulation: A report of two cases
    Ren-Ze Huang, Nuo Chen, Yan Hu, Wan-Ming Hu, Feng-Hua Wang, Dong-Liang Chen
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Comparative analysis of systemic oncological treatments and best supportive care for advanced gastresophageal cancer: A comprehensive scoping review and evidence map
    Santero Marilina, Meade Adriana, Selva Anna, Acosta‐Dighero Roberto, Meza Nicolás, Quintana Maria Jesús, Bracchiglione Javier, Requeijo Carolina, Salazar Josefina, Rodríguez Grijalva Gerardo, Solà Ivan, Urrútia Gerard, Bonfill Cosp Xavier
    Journal of Evidence-Based Medicine.2023; 16(2): 216.     CrossRef
  • Clinicopathologic features and prognosis of 71 patients with gastric cancer and disseminated intravascular coagulation
    Ling Chen, Jing Lin, Yu Chen, Jiami Yu, Xiaojie Wang
    PeerJ.2023; 11: e16527.     CrossRef
  • Docetaxel and Fluorouracil as First-Line Therapy for Gastric Cancer with Bone Marrow Metastasis and Disseminated Intravascular Coagulation
    Zhai Xiaohui, Li Shanshan, Cao Taiyuan, Du Ge, Yu Hongen, Shi Lishuo, Lin Xiaoru, Hong Wanjia, Xiao Jian
    Future Oncology.2022; 18(35): 3875.     CrossRef
  • A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
    Mayu Kobayashi, Hideo Wada, Shunsuke Fukui, Hiroki Mizutani, Yuhuko Ichikawa, Katsuya Shiraki, Isao Moritani, Hidekazu Inoue, Motomu Shimaoka, Hideto Shimpo
    Journal of Clinical Medicine.2021; 10(22): 5352.     CrossRef
  • Understanding and treating solid tumor–related disseminated intravascular coagulation in the “era” of targeted cancer therapies
    Felice Vito Vitale, Giuseppe SA Longo-Sorbello, Stefano Rotondo, Francesco Ferrau
    SAGE Open Medicine.2017;[Epub]     CrossRef
  • Advanced gastric cancer linitis plastica presented with disseminated intravascular coagulation
    Sehem Ghazala, Jawad Bilal, Irbaz Bin Riaz
    BMJ Case Reports.2016; : bcr2016217675.     CrossRef
  • Efficacy and Safety of Weekly Paclitaxel Therapy for Advanced Gastric Cancer Patients with Disseminated Intravascular Coagulation
    Sadayuki Kawai, Yasuhiro Sakamoto, Yoshikazu Takahashi, Sonoko Ichikawa, Makio Gamoh
    Journal of Gastrointestinal Cancer.2015; 46(4): 438.     CrossRef
  • D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
    Se-Il Go, Min Jeong Lee, Won Sup Lee, Hye Jung Choi, Un Seok Lee, Rock Bum Kim, Myoung Hee Kang, Hoon-Gu Kim, Gyeong-Won Lee, Jung Hun Kang, Jeong-Hee Lee, Sun Joo Kim
    Medicine.2015; 94(30): e951.     CrossRef
  • 13,657 View
  • 103 Download
  • 13 Web of Science
  • 11 Crossref
Close layer
A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal Carcinomatosis
Dong Hyun Lee, Sung Yong Oh, Yu Rim Lee, Seok Jae Huh, Hyun Hwa Yoon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Young Kim, Hyo-Jin Kim, Hyuk-Chan Kwon
Cancer Res Treat. 2011;43(4):225-230.   Published online December 27, 2011
DOI: https://doi.org/10.4143/crt.2011.43.4.225
AbstractAbstract PDFPubReaderePub
PURPOSE
Peritoneal carcinomatosis (PC) of colorectal cancer (CRC) is common and is the second most common cause of death. Clinical studies regarding chemotherapy for CRC with PC have been classically rather limited in scope. We evaluated the efficacy of modified oxaliplatin, leucovorin, and fluorouracil (m-FOLFOX4) regimen for PC of CRC origin.
MATERIALS AND METHODS
CRC patients with PC were treated with cycles of oxaliplatin at 85 mg/m2 on day 1, leucovorin 20 mg/m2 followed by 5-fluorouracil (5-FU) via a 400 mg/m2 bolus and a 22 hours continuous infusion of 600 mg/m2 5-FU on days 1-2 at 2-week intervals.
RESULTS
Forty patients participated in this study. Median age was 55 years. Thirty-two patients (80.0%) received previous operation, and 60.0% of PC occurred synchronously. Thirty-five patients (87.5%) were assessable and exhibited measurable lesions. Two patients (5.7%) demonstrated complete response and five patients (14.3%) showed partial response. The median time to progression was 4.4 months (95% confidence interval, 2.5 to 6.3 months), the median overall survival time was 21.5 months (95% confidence interval, 17.2 to 25.7 months). There was no treatment related death. Presence of liver metastasis (p=0.022), performance status (p=0.039), and carcinoembryonic antigen level (p=0.016) were related to the time to progression. Patients with low carcinoembryonic antigen level (37.2 months vs. 15.6 months, p=0.001) or good performance status (22.5 months vs. 6.8 months, p=0.040) showed better overall survival.
CONCLUSION
The m-FOLFOX4 regimen was determined to be effective for CRC patients with PC.

Citations

Citations to this article as recorded by  
  • Results of complete cytoreductive strategy in patients with peritoneal metastases of colorectal origin with or without extraperitoneal metastases: A bicentric analysis
    Isabelle Sourrouille, Clément Pastier, Maximilliano Gelli, Léonor Benhaïm, Pierre Cattan, Michel Ducreux, Thomas Aparicio, Diane Goéré
    European Journal of Surgical Oncology.2025; 51(1): 108788.     CrossRef
  • Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis
    Udit Nindra, Adel Shahnam, Kate L. Mahon
    Asia-Pacific Journal of Clinical Oncology.2022; 18(1): 7.     CrossRef
  • Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial
    Gabriel Glockzin, Florian Zeman, Roland S. Croner, Alfred Königsrainer, Jörg Pelz, Michael A. Ströhlein, Beate Rau, Dirk Arnold, Michael Koller, Hans J. Schlitt, Pompiliu Piso
    Clinical Colorectal Cancer.2018; 17(4): 285.     CrossRef
  • Treatment of peritoneal metastases from small bowel adenocarcinoma
    Koen P. Rovers, Eelco de Bree, Yutaka Yonemura, Ignace H. de Hingh
    International Journal of Hyperthermia.2017; 33(5): 571.     CrossRef
  • Percutaneous lung ablation of pulmonary recurrence may improve survival in selected patients undergoing cytoreductive surgery for colorectal cancer with peritoneal carcinomatosis
    T.A. Bin Traiki, O.M. Fisher, S.J. Valle, R.N. Parikh, M.A. Kozman, D. Glenn, M. Power, W. Liauw, N.A. Alzahrani, D.L. Morris
    European Journal of Surgical Oncology (EJSO).2017; 43(10): 1939.     CrossRef
  • Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis
    C. Demtröder, W. Solass, J. Zieren, D. Strumberg, U. Giger‐Pabst, M.‐A. Reymond
    Colorectal Disease.2016; 18(4): 364.     CrossRef
  • Therapeutic options for peritoneal metastasis arising from colorectal cancer
    Gabriel Glockzin, Hans J Schlitt, Pompiliu Piso
    World Journal of Gastrointestinal Pharmacology and Therapeutics.2016; 7(3): 343.     CrossRef
  • Challenges in the multidisciplinary management of stage IV colon and rectal cancer
    Pompiliu Piso, Dirk Arnold, Gabriel Glockzin
    Expert Review of Gastroenterology & Hepatology.2015; 9(3): 317.     CrossRef
  • Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis
    Gabriel Glockzin, Michael Gerken, Sven A Lang, Monika Klinkhammer-Schalke, Pompiliu Piso, Hans J Schlitt
    BMC Cancer.2014;[Epub]     CrossRef
  • Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
    H. Ishida, K. Kumamoto, K. Ishibashi, S. Hatano, T. Matsuzawa, N. Okada, Y. Kumagai, H. Baba, N. Haga
    Techniques in Coloproctology.2013; 17(6): 647.     CrossRef
  • Peritoneal carcinomatosis of colorectal origin: is it really an end-stage disease?
    E. Chouillard, V. Greco, N. Tsiminikakis
    Techniques in Coloproctology.2013; 17(6): 619.     CrossRef
  • Peritoneal carcinomatosis from colorectal cancer: hyperthermic intraperitoneal chemotherapy and the role of systemic chemotherapy
    Michael Michael
    Colorectal Cancer.2013; 2(5): 449.     CrossRef
  • Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer
    Jan Franko, Charles D. Goldman, Kiran K. Turaga
    Current Colorectal Cancer Reports.2013; 9(3): 242.     CrossRef
  • A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial
    Gabriel Glockzin, Justine Rochon, Dirk Arnold, Sven A Lang, Frank Klebl, Florian Zeman, Michael Koller, Hans J Schlitt, Pompiliu Piso
    BMC Cancer.2013;[Epub]     CrossRef
  • A Long Survived Case of Transverse Colon Cancer with Peritoneal Dissemination Treated by Multidisciplinary Treatment Including Hyperthermic Intraperitoneal Chemotherapy
    Toshiyuki Nakazawa, Takanori Goi, Mituhiro Morikawa, Kenji Koneri, Makoto Murakami, Yasuo Hirono, Atushi Iida, Kanji Katayama, Akio Yamaguchi, Atomu Murai
    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons).2012; 37(6): 1136.     CrossRef
  • 11,716 View
  • 62 Download
  • 15 Crossref
Close layer
Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection
Ji Hyun Lee, Min-Chan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Sung-Hyun Kim, Kyung A Kwon, Suee Lee, Jin Sook Jeong, Seok-Reyol Choi, Hyo-Jin Kim
Cancer Res Treat. 2011;43(2):117-123.   Published online June 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.2.117
AbstractAbstract PDFPubReaderePub
PURPOSE
To assess the usefulness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy.
MATERIALS AND METHODS
Sixty-two patients underwent curative surgical resection between January, 2006 and December, 2008. Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49 had successful assay results and they received either oral 5-fluorouracil or other chemotherapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-fluorouracil and whose assays were successful.
RESULTS
The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years (range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-group showed a significantly longer time to relapse (not reached in the sensitive-group vs. 24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group, p=0.16, statistically insignificant).
CONCLUSION
Patients who receive curative surgical resection significantly benefit from sensitive adjuvant chemotherapy according to ATP-CRA results for time to relapse.

Citations

Citations to this article as recorded by  
  • In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
    Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
    Cancer Research and Treatment.2016; 48(3): 970.     CrossRef
  • Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
    Sang Hun Jung, So Hyun Kim, Jae Hwang Kim
    Korean Journal of Clinical Oncology.2015; 11(2): 51.     CrossRef
  • Purinergic signalling in the gastrointestinal tract and related organs in health and disease
    Geoffrey Burnstock
    Purinergic Signalling.2014; 10(1): 3.     CrossRef
  • Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes
    KOJI HARADA, TARANNUM FERDOUS, YOSHIYA UEYAMA
    International Journal of Oncology.2014; 44(4): 1302.     CrossRef
  • Purinergic signalling and cancer
    Geoffrey Burnstock, Francesco Di Virgilio
    Purinergic Signalling.2013; 9(4): 491.     CrossRef
  • Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines
    KAZUYA UCHIBORI, ATSUSHI KASAMATSU, MASAHIKO SUNAGA, SATOSHI YOKOTA, TOMOYA SAKURADA, ERIKO KOBAYASHI, MASAHARU YOSHIKAWA, KATSUHIRO UZAWA, SHIRO UEDA, HIDEKI TANZAWA, NOBUNORI SATO
    International Journal of Oncology.2012; 40(4): 1005.     CrossRef
  • 11,444 View
  • 46 Download
  • 6 Crossref
Close layer
Case Report
A Case of 5-Fluorouracil Induced Encephalopathy
Kyung A Kwon, Hyuk-Chan Kwon, Min Chan Kim, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hyo-Jin Kim
Cancer Res Treat. 2010;42(2):118-120.   Published online June 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.2.118
AbstractAbstract PDFPubReaderePub

Patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at risk for experiencing serious adverse effects following 5-fluorouracil (5-FU) based chemotherapy. Neurotoxicity is considered an extremely rare side effect of 5-FU. We report here on an unusual case of 5-FU induced encephalopathy. A 38-year-old woman with advanced gastric carcinoma was treated with adjuvant chemotherapy that consisted of infused 5-FU (1,000 mg/m2) for 5 days and cisplatin (60 mg/m2) on day 1 following total gastrectomy. Nineteen days after starting chemotherapy, the patient displayed a sudden onset of slurred speech, confusion, cognitive disturbances and paranoia. A magnetic resonance image (MRI) of the brain showed no structural abnormalities, and the other laboratory tests provided no explanations for her symptoms, other than a slightly elevated ammonia level. The patient was treated with a lactulose retention enema and thiamine infusion, the 5-FU was halted and her symptoms then recovered after 7 days.

Citations

Citations to this article as recorded by  
  • Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
    Ana Dias-Carvalho, Mariana Ferreira, Rita Ferreira, Maria de Lourdes Bastos, Susana Isabel Sá, João Paulo Capela, Félix Carvalho, Vera Marisa Costa
    Archives of Toxicology.2022; 96(1): 11.     CrossRef
  • Chemotherapy-Induced Acute Reversible Toxic Leukoencephalopathy
    A. K. Vishnu, Thara Pratap, Dhanya Jacob, Muhammed Jasim Abdul Jalal, Anupama Gopalakrishnabhakthan
    Current Medical Issues.2022; 20(3): 194.     CrossRef
  • Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation
    Hemnishil K. Marella, Rahul Peravali, Amit L. Jain, Satheesh Nair, Benedict Maliakkal, Uchenna Agbim, Rajanshu Verma
    Baylor University Medical Center Proceedings.2020; 33(2): 256.     CrossRef
  • Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
    Claudia Pellacani, Georgios Eleftheriou
    Advances in Medical Sciences.2020; 65(2): 265.     CrossRef
  • Thiamine deficiency in the outpatient psychiatric oncology setting: A case series
    Rose Zhang, Sudhakar Tummala, Deepti Chopra
    Palliative and Supportive Care.2020; 18(5): 609.     CrossRef
  • 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy
    Alice Boilève, Camille Wicker, Benjamin Verret, Florence Leroy, David Malka, Mathieu Jozwiak, Clément Pontoizeau, Chris Ottolenghi, Pascale De Lonlay, Michel Ducreux, Antoine Hollebecque
    Anti-Cancer Drugs.2019; 30(3): 313.     CrossRef
  • An imaging-based review of systemic therapies and associated toxicities in metastatic pancreatic cancer as per the 2018 ASCO guidelines: what every radiologist should know
    Daniel A. Smith, Bhanusupriya Somarouthu, Nikhil H. Ramaiya
    Abdominal Radiology.2019; 44(6): 2182.     CrossRef
  • A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole
    Tatsuya Fukumoto, Fumiaki Katada, Susumu Sato, Hidehiro Shibayama, Shigeo Murayama, Toshio Fukutake
    Rinsho Shinkeigaku.2018; 58(2): 118.     CrossRef
  • The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate
    Cynthia Santos, Brent W. Morgan, Robert J. Geller
    The American Journal of Emergency Medicine.2017; 35(5): 802.e7.     CrossRef
  • Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
    Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, Véronique Guerin-Meyer, Oana Cojocarasu, Ce
    Seminars in Oncology.2017; 44(1): 13.     CrossRef
  • Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy
    Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Keiji Sugiyama, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Yozo Sato, Hidekazu Yamaura, Yoshitaka Inaba, Makoto Ishihara, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
    Medicine.2017; 96(22): e6874.     CrossRef
  • Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy
    May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti
    The American Journal of Emergency Medicine.2017; 35(9): 1389.     CrossRef
  • Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology
    Yuichiro Kitai, Takeshi Matsubara, Taro Funakoshi, Takahiro Horimatsu, Manabu Muto, Motoko Yanagita
    Renal Replacement Therapy.2016;[Epub]     CrossRef
  • Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer
    Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Abdülsamet Erden
    Journal of Oncology Pharmacy Practice.2015; 21(1): 72.     CrossRef
  • Subacute reversible toxic encephalopathy related to treatment with capecitabine: A case report with literature review and discussion of pathophysiology
    E. Lyros, S. Walter, I. Keller, P. Papanagiotou, K. Fassbender
    NeuroToxicology.2014; 42: 8.     CrossRef
  • Epilepsy in women with gynecologic malignancies
    Yixue Gu, Qin Yang, Xuefeng Wang
    Expert Review of Neurotherapeutics.2014; 14(5): 503.     CrossRef
  • Posterior Reversible Encephalopathy Syndrome (PRES) After Treatment With Oxaliplatin and 5-Fluorouracil
    Nicholas Truman, Daniel Nethercott
    Clinical Colorectal Cancer.2013; 12(1): 70.     CrossRef
  • 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases
    Pierre-Yves Cordier, André Nau, Joseph Ciccolini, Manuela Oliver, Cédric Mercier, Bruno Lacarelle, Eric Peytel
    Cancer Chemotherapy and Pharmacology.2011; 68(3): 823.     CrossRef
  • 11,318 View
  • 97 Download
  • 18 Crossref
Close layer
Original Articles
Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer
Jung Hwan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Suee Lee, Sung-Hyun Kim, Dae-Cheol Kim, Jin-Hwa Lee, Hyung-Sik Lee, Se-Heun Cho, Hyo-Jin Kim
Cancer Res Treat. 2008;40(3):101-105.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.101
AbstractAbstract PDFPubReaderePub
Purpose

Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane.

Materials and Methods

We evaluated the use of a GP regimen (1,000 mg/m2 gemcitabine administered on days 1 and 8 plus 60 mg/m2 cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy.

Results

The median patient age was 49 years (age range, 35~69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14~44%). The median time to progression was 5.2 months (95% CI, 3.6~6.8 months). Median survival was 19.5 months (95% CI, 11.2~27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths.

Conclusions

Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.

Citations

Citations to this article as recorded by  
  • Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
    Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
    The Korean Journal of Internal Medicine.2021; 36(1): 182.     CrossRef
  • Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
    Jinfeng Zhang, Mingxi Lin, Yizi Jin, Linhan Gu, Ting Li, Baoying Yuan, Biyun Wang, Leiping Wang, Sheng Zhang, Jun Cao, Zhonghua Tao, Jian Zhang, Xichun Hu
    Breast Cancer Research and Treatment.2020; 182(3): 719.     CrossRef
  • Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
    Jung Sun Kim, In Hae Park, Keun Seok Lee, Jungsil Ro
    Journal of Breast Cancer.2014; 17(4): 339.     CrossRef
  • A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
    Pramod K. Julka, Raju T. Chacko, Shona Nag, Rajinder Parshad, Aravindan Nair, Chaitanyanand B. Koppiker, Fen Chao Richard Xue, Helen Barraclough, Navreet Dhindsa, Anil Seth, Anurita Majumdar, Tarun Puri
    Breast Cancer.2013; 20(4): 357.     CrossRef
  • Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Tao Wang, Shaohua Zhang, Min Zeng, Xinyou Lu, Ge Shen, Shikai Wu, Santai Song, Zefei Jiang
    Medical Oncology.2012; 29(1): 56.     CrossRef
  • Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    H J Stemmler, D diGioia, W Freier, H W Tessen, G Gitsch, W Jonat, W Brugger, E Kettner, W Abenhardt, H Tesch, H J Hurtz, S Rösel, O Brudler, V Heinemann
    British Journal of Cancer.2011; 104(7): 1071.     CrossRef
  • Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
    Ali I. Shamseddine, Fadi S. Farhat
    Chemotherapy.2011; 57(6): 468.     CrossRef
  • Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    Binghe Xu, Zefei Jiang, Sung-Bae Kim, Shiying Yu, Jifeng Feng, Artur Malzyner, Auro del Giglio, Hyun C. Chung, Li Jun Shen, Daniel Lee Kay Pen
    Breast Cancer.2011; 18(3): 203.     CrossRef
  • 10,658 View
  • 67 Download
  • 8 Crossref
Close layer
Gemcitabine versus Gemcitabine Combined with Cisplatin Treatment Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Analysis
Jae-Hyuk Choi, Sung Yong Oh, Hyuk-Chan Kwon, Jung Hwan Kim, Jae Hoon Lee, Suee Lee, Dong Mee Lee, Sung-Hyun Kim, Myung Hwan Rho, Young-Hoon Kim, Mee-Sook Rho, Hyo-Jin Kim
Cancer Res Treat. 2008;40(1):22-26.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.22
AbstractAbstract PDFPubReaderePub
Purpose

Gemcitabine is the most active agent to treat unresectable pancreatic cancer. The superiority of combining other drugs with cisplatin is still controversial; therefore, we performed a retrospective analysis of gemcitabine versus gemcitabine combined with cisplatin to determine the treatment outcomes for patients with locally advanced or metastatic pancreatic cancer.

Materials and Methods

From 2001 to 2007, we enrolled 60 patients who were treated with gemcitabine or gemcitabine combined with cisplatin for locally advanced or metastatic pancreatic cancer. Gemcitabine 1, 000 mg/m2 (G) was administrated at day 1 and day 8 every 3 weeks. Cisplatin 60 mg/m2 was added at day 1 every 3 weeks to the gemcitabine schedule (GP).

Results

Number of G: GP was 34: 26, locally advanced to metastatic ratio was 35% to 65% in group G and 46% to 54% in group GP. Median follow up duration was 29 months. The median number of chemotherapy cycles was 4 (range: 2~11) for the G group, and 4 (range: 1~11) for the GP group. The response rate of the G and GP groups was 17% and 11%, respectively. The progression free survival (PFS) was 4.5 months and 2.8 months, respectively, for the G and GP groups. The overall survival (OS) was 10.7 and 8.7 months respectively, for the G and GP groups, but there is no statistically significant difference of the PFS (p=0.2396) and OS (p=0.4643) between the 2 groups. The hematological toxicity profile was similar (the grade III neutropenia and thrombocytopenia was 4.4% and 3.1%, respectively, in G group, and 7.5% and 2.8%, respectively, in the GP group). But non-hematological toxicities such as skin rash, abnormal liver function and nausea/vomiting were observed in 3 patients of the GP group. On the prognostic factor analysis, no factors predicted a longer PFS and OS for both the G and GP groups.

Conclusions

Gemcitabine single treatment might be more tolerable and it had the same efficacy compared to cisplatin combination treatment in this retrospective study.

Citations

Citations to this article as recorded by  
  • Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies
    David J. Kuter
    Haematologica.2022; 107(6): 1243.     CrossRef
  • Treatment of drug-induced immune thrombocytopenias
    Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul
    Haematologica.2022; 107(6): 1264.     CrossRef
  • Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer
    Giuseppe Belfiore, Maria Paola Belfiore, Alfonso Reginelli, Raffaella Capasso, Francesco Romano, Giovanni Pietro Ianniello, Salvatore Cappabianca, Luca Brunese
    Medical Oncology.2017;[Epub]     CrossRef
  • Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
    Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Steffen Doerfel, Paul Burgess, Stacey Kalambakas, Yasser Mostafa Kamel, Frederic Forget
    International Journal of Hematology.2017; 106(6): 765.     CrossRef
  • Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study
    Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam, Yasser Mostafa Kamel
    Cancer Medicine.2015; 4(1): 16.     CrossRef
  • Comparison of Gemcitabine Combined With Targeted Agent Therapy Versus Gemcitabine Monotherapy in the Management of Advanced Pancreatic Cancer
    Qin Li, Zhenyan Yuan, Han Yan, Zhaoyang Wen, Ruixue Zhang, Bangwei Cao
    Clinical Therapeutics.2014; 36(7): 1054.     CrossRef
  • Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
    Qin Li, Han Yan, Wenting Liu, Hongchao Zhen, Yifan Yang, Bangwei Cao, Jonathan R. Brody
    PLoS ONE.2014; 9(8): e104346.     CrossRef
  • Oncolytic Activity of Avian Influenza Virus in Human Pancreatic Ductal Adenocarcinoma Cell Lines
    Samantha B. Kasloff, Matteo S. Pizzuto, Micol Silic-Benussi, Silvia Pavone, Vincenzo Ciminale, Ilaria Capua, K. L. Beemon
    Journal of Virology.2014; 88(16): 9321.     CrossRef
  • Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
    Wenbo Zhu, Jingjie Li, Sihan Wu, Shifeng Li, Liang Le, Xingwen Su, Pengxin Qiu, Haiyan Hu, Guangmei Yan
    Pancreas.2012; 41(7): 1029.     CrossRef
  • 11,381 View
  • 57 Download
  • 9 Crossref
Close layer
Case Reports
Unusual Presentation of Large B Cell Lymphoma- Bone and Stomach- Treated with Autologous Transplantation
Bokyung Kim, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Sook Hee Hong, Sung-Soo Kim, Hyo-Jin Kim
Cancer Res Treat. 2007;39(4):181-184.   Published online December 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.4.181
AbstractAbstract PDFPubReaderePub

Extranodal presentation of diffuse large B cell lymphoma (DLBL) is frequently observed in the gastrointestinal tract, CNS, bone, testes and liver. However, the simultaneous detection of multiple extranodal involvement at presentation is quite an uncommon occurrence. In this study, we report on a patient with an uncommon presentation of DLBL, and he had symptoms of left knee joint pain and hematemesis, characterized by bone and stomach involvement. Computed tomography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning revealed a rapid, extensive spread to the bones and soft tissues. Subsequent histopathological examination verified the bony and gastric CD20-positive DLBL localization. We diagnosed this case as DLBL of stage IV with an international prognostic index of 3, and classified him into the high intermediate risk group. This patient was treated via chemotherapy with an R-CHOP regimen. After achieving a partial response, the patient received autologous peripheral blood stem cell transplantation. The patient attained partial remission, as shown on the FDG-PET scan, and he displayed improvement of his left femur pain.

  • 9,122 View
  • 50 Download
Close layer
Extraskeletal Mesenchymal Chondrosarcoma of the Heart Responded to Systemic Chemotherapy: A Case Report
Chien Ter Hsing, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Tae-Ho Park, Jong Soo Woo, Seo Hee Na, Hyo-Jin Kim
Cancer Res Treat. 2007;39(3):131-133.   Published online September 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.3.131
AbstractAbstract PDFPubReaderePub

Mesenchymal chondrosarcoma is a rare cartilaginous ne - oplasm of an extraskeletal origin, and this predominately occurs in the head and neck, and also in the lower extremities. Fewer than twenty cases of cardiac mesenchymal chondrosarcoma have so far been reported on. For the most part, the results of treatment for patients with this condition have been dismal. In this study, we describe a case of cardiac mesenchymal chondrosarcoma that responded to chemotherapy following surgical biopsy. A 46-year-old man was referred for evaluation of his pleural effusions in both lungs. Chest computed tomography revealed an ovoid-shaped mass in the posterior wall of the patient's left atrium. The echocardiogram revealed a large ovoid-shaped immobile mass (11×6 cm2) in the pericardiac space, which was attached to the posterior wall of the left atrium. Emergency pericardiostomy with closure thoracostomy was performed. Seven days later, a thoracotomy was performed for reduction and diagnosis of the cardiac mass. The pathological diagnosis was extraskeletal mesenchymal chondrosarcoma of the heart.. Postoperative chemotherapy was performed for the huge remaining mass with a combined regimen of etoposide, ifosfamide and cisplatin. After 6 cycles, the patient showed a partial response without symptoms. Although cardiac mesenchymal chondrosarcoma has been reported to be chemotherapy-resistant with a short survival duration, chemotherapy may prove to be an effective treatment modality.

Citations

Citations to this article as recorded by  
  • Unusual Presentation of Extraskeletal Mesenchymal Chondrosarcoma: A Case Report
    Mathilde Bernard, Ramy Samargandi
    Cureus.2023;[Epub]     CrossRef
  • Mesenchymal chondrosarcoma: imaging features and clinical findings
    Soleen Ghafoor, Meera R. Hameed, William D. Tap, Sinchun Hwang
    Skeletal Radiology.2021; 50(2): 333.     CrossRef
  • 18F-FDG PET/CT Findings of Mesenchymal Chondrosarcoma of the Orbit
    Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
    Clinical Nuclear Medicine.2018; 43(2): e43.     CrossRef
  • Mesenchymal chondrosarcoma of the orbit: imaging features of CT and MRI
    Mitsuteru Tsuchiya, Takayuki Masui, Yoshiro Otsuki, Harumi Sakahara
    The British Journal of Radiology.2018; 91(1090): 20170579.     CrossRef
  • Radiofrequency ablation of metastatic chondrosarcoma-associated refractory ventricular tachycardia originating from the right ventricular outflow tract: A case report and literature review
    Xiangmin Shi, Zhuo Liang, Jian Li, Jianping Guo, Zhaoliang Shan, Yutang Wang
    Experimental and Therapeutic Medicine.2016; 12(3): 1803.     CrossRef
  • A Rare Case of Extraskeletal Mesenchymal Chondrosarcoma with Dedifferentiation Arising from the Buccal Space in a Young Male
    Shalini R. Gupta, Ravinder K. Saran, Pankaj Sharma, Aadithya B. Urs
    Journal of Maxillofacial and Oral Surgery.2015; 14(S1): 293.     CrossRef
  • Mesenchymal Chondrosarcoma of Bone and Soft Tissue: A Systematic Review of 107 Patients in the Past 20 Years
    Jie Xu, Dasen Li, Lu Xie, Shun Tang, Wei Guo, David M Loeb
    PLOS ONE.2015; 10(4): e0122216.     CrossRef
  • A fatal case of primary cardiac chondrosarcoma presenting with amaurosis fugax
    Jens Sundbøll, Nils Henrik Stubkjær Hansson, Steen Baerentzen, Manan Pareek
    BMJ Case Reports.2015; : bcr2015212178.     CrossRef
  • Extraskeletal Intraspinal Mesenchymal Chondrosarcoma; 18F-FDG PET/CT Finding
    EunSeong Lee, Ho Young Lee, Gheeyoung Choe, Ki-Jeong Kim, Won Woo Lee, Sang Eun Kim
    Clinical Nuclear Medicine.2014; 39(1): e64.     CrossRef
  • Management of renal extraskeletal mesenchymal chondrosarcoma
    Vitalie Gherman, Ciprian Tomuleasa, Catalina Bungardean, Nicolae Crisan, Victor-Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman
    BMC Surgery.2014;[Epub]     CrossRef
  • Primary Cardiac Chondrosarcoma
    Guofei Zhang, Xiaofan Chen, Lei Guo, Qiang Feng, Yiming Ni
    Journal of Cardiac Surgery.2012; 27(2): 186.     CrossRef
  • 9,482 View
  • 52 Download
  • 11 Crossref
Close layer
Original Articles
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Res Treat. 2007;39(1):6-9.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.6
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the therapeutic activity and safety of paclitaxel and cisplatin combination chemotherapy in patients with advanced or metastatic gastric cancers that are unresponsive to primary chemotherapy.

Materials and Methods

Advanced or metastatic gastric cancer patients unresponsive to first line chemotherapy were entered into this trial. The treatment regimen consisted of paclitaxel, 175 mg/m2 by 3-hour infusion on day 1, and cisplatin, 60 mg/m2 by 1 hour infusion on day 1, with the treatment repeated every 3 weeks.

Results

37 patients were entered in this study, with 32 fully evaluable for response. 4 (13%), 13 (40%) and 15 (47%) patients achieved a partial response, stable disease and progressed, respectively. The median time to progression was 4.0 months (95% CI: 2.0~6.0 months), and the median overall survival was 12.6 months (95% CI: 5.5~19.7 months), with a 1-year survival rate of 54%. Of a total of 135 cycles of chemotherapy, grades 3 and 4 hematological toxicities were neutropenia (14%) and anemia (3%). Grade ≥2 neuropathy was observed in 6 patients (17%).

Conclusion

The combination of paclitaxel and cisplatin is an effective and tolerable salvage treatment modality for advanced gastric cancer.

Citations

Citations to this article as recorded by  
  • Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
    Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
    Cancer Management and Research.2022; Volume 14: 2825.     CrossRef
  • Multi-center Phase II Trial of Weekly Paclitaxel Plus Cisplatin Combination Chemotherapy in Patients with Advanced Gastric and Gastro-esophageal Cancer
    Q. Sun, C. Liu, H. Zhong, B. Zhong, H. Xu, W. Shen, D. Wang
    Japanese Journal of Clinical Oncology.2009; 39(4): 237.     CrossRef
  • 9,182 View
  • 45 Download
  • 2 Crossref
Close layer
Prolonged Oral Etoposide in Combination with Intravenous Cisplatin for Advanced Non-small Cell Lung Cancer
Ki Hyun Kim, Sung Yong Oh, Hun Sik Jeong, Jong Tae Lee, Won Seng Kim, Ho Joong Kim, Sung Soo Yoon, Won Ki Kang, Hong Ghi Lee, Chong Heon Lee, Chan Hyung Park, Keun Chil Park
J Korean Cancer Assoc. 1999;31(1):105-111.
AbstractAbstract PDF
PURPOSE
Etoposide is a schedule-dependent agent and has a synergistic activity with cisplatin. We evaluated the response rate and the toxicity of prolonged oral etoposide in combination with intravenous cisplatin for the previously untreated patients with unresectable stage IIIB or IV non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
Between April 1996 and February 1998, 71 patients were enrolled. The median age was 61 years (range, 36~75) and male: female ratio was 54: 17. Fourteen patients had stage IIIB disease and 57 had stage IV. Sixty-two patients had ECOG performance status of 0 or 1, and 9 had 2. Forty-eight patients had adenocarcinoma, 19 had squamous cell carcinoma and 4 had poorly differentiated NSCLC. Treatment consists of daily oral etoposide 50 mg/m in 2 divided doses for 21 days and intravenous cisplatin 60 mg/m on day 1. The treatment was repeated every 28 days.
RESULTS
Sixty-four of 71 patients were evaluable. Complete response and partial response were observed in 1 and 21 patients, respectively. The overall response rate was 34.4% (95% confidence interval 23.9~46.6%) and the median response duration was 30 weeks (range 13-53 weeks). The median survival of 71 patients was 56 weeks (range 3. 96+ weeks). There was a significantly longer survival in responders (p=0.035). Toxicities were evaluated by WHO criteria. Hematologic toxicities of grade 3, 4 were as follows: anemia 12.3%, leukopenia 8.7%, neutropenia 19.2%, thrombocytopenia 1.8%. Non-hematologic toxicities of grade 3, 4 were as follows: nausea and vomiting 5.9%, stomatitis 14.7%, diarrhea 1.5%. Early treatment-related death occurred in 2 patients (2.8%) due to sepsis.
CONCLUSION
Combination chemotherapy with prolonged oral etoposide and intravenous cisplatin is easy to administer and has moderate activity with acceptable toxicities for NSCLC.
  • 2,809 View
  • 14 Download
Close layer
Cancer Res Treat : Cancer Research and Treatment
© Korean Cancer Association.
Close layer
TOP